STOCK TITAN

Theriva Biologics (TOVX) 10-K Filings

TOVX NYSE

Here are the 10-K annual reports from Theriva Biologics, Inc. (TOVX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow TOVX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TOVX filings page.

Rhea-AI Summary

Theriva Biologics, Inc. outlines its transformation into an oncology-focused, clinical-stage company centered on oncolytic adenovirus candidate VCN-01 (zabilugene almadenorepvec) for solid tumors, led by metastatic pancreatic ductal adenocarcinoma and retinoblastoma.

The 10-K highlights positive Phase 2b VIRAGE data in first-line metastatic pancreatic cancer, where VCN-01 plus gemcitabine/nab-paclitaxel improved overall and progression-free survival versus chemotherapy alone, with greater benefit in patients receiving two VCN-01 doses. Regulators in the U.S. and Europe granted Orphan Drug and Fast Track designations and provided guidance supporting a single pivotal Phase 3 trial using VCN-01 with gemcitabine/nab-paclitaxel.

Theriva also reports encouraging Phase 1 results for intravitreal VCN-01 in refractory retinoblastoma, including Orphan and Rare Pediatric Disease designations and a potential priority review voucher if ultimately approved. Beyond VCN-01, the company is advancing next-generation virus VCN-12 and a THERICEL suspension cell platform to scale viral manufacturing. In parallel, Theriva has de-emphasized its gastrointestinal pipeline, licensing SYN-020 globally to Rasayana Therapeutics and seeking partners for SYN-004, while retaining milestone, royalty and sublicense economics.